

Author index

Volume 49 (2001)

-
- Abe, Y., see Takahashi, K. 49, 15
- Andreone, P., S. Fiorino, C. Cursaro, A. Gramenzi, M. Margotti, L. Di Giammarino, M. Biselli, R. Miniero, G. Gasbarrini, M. Bernardi, Vitamin E as treatment for chronic hepatitis B: results of a randomized controlled pilot trial 49, 75
- Baron, S., see Singh, I.P. 49, 157
- Bender, W., see Weber, O. 49, 179
- Bernardi, M., see Andreone, P. 49, 75
- Beth-Giraldo, E., see Buonaguro, L. 49, 35
- Biselli, M., see Andreone, P. 49, 75
- Buonaguro, F.M., see Buonaguro, L. 49, 35
- Buonaguro, L., F.M. Buonaguro, M.L. Tornesello, D. Mantas, E. Beth-Giraldo, R. Wagner, S. Michelson, M.-C. Prevost, H. Wolf, G. Giraldo, High efficient production of Pr55^{gag} virus-like particles expressing multiple HIV-1 epitopes, including a gp120 protein derived from an Ugandan HIV-1 isolate of subtype A 49, 35
- Chopra, A.K., see Singh, I.P. 49, 157
- Cinatl, J., see Scholz, M. 49, 129
- Clercq, E.D., see Neyts, J. 49, 121
- Copenhagen, D.H., see Singh, I.P. 49, 157
- Cursaro, C., see Andreone, P. 49, 75
- De Bolle, L., see Neyts, J. 49, 115
- De Clercq, E., see Neyts, J. 49, 115
- Di Giammarino, L., see Andreone, P. 49, 75
- Doerr, H.W., see Scholz, M. 49, 129
- Domagala, J., see Sharmeen, L. 49, 101
- Eckenberg, P., see Weber, O. 49, 179
- Eizuru, Y., see Minematsu, T. 49, 25
- Fiorino, S., see Andreone, P. 49, 75
- Flower, R.L.P., see Semple, S.J. 49, 169
- Gasbarrini, G., see Andreone, P. 49, 75
- Giraldo, G., see Buonaguro, L. 49, 35
- Gogliotti, R., see Sharmeen, L. 49, 101
- Goldmann, S., see Weber, O. 49, 179
- Gracheck, S., see Sharmeen, L. 49, 101
- Gramenzi, A., see Andreone, P. 49, 75
- Haerter, M., see Weber, O. 49, 179
- Hallenberger, S., see Weber, O. 49, 179
- Hayden, F.G., see Zambon, M. 49, 147
- Heath, A.W., see Mohamedi, S.A. 49, 83
- Heldsinger, A., see Sharmeen, L. 49, 101
- Henke, A., R. Zell, A. Stelzner, DNA vaccine-mediated immune responses in Coxsackie virus B3-infected mice 49, 49
- Henninger, K., see Weber, O. 49, 179
- Jennings, R., see Mohamedi, S.A. 49, 83
- Mantas, D., see Buonaguro, L. 49, 35
- Margotti, M., see Andreone, P. 49, 75
- Matsuda, M., see Takahashi, K. 49, 15
- McQuade, T., see Sharmeen, L. 49, 101
- Michelson, S., see Buonaguro, L. 49, 35
- Minamishima, Y., see Minematsu, T. 49, 25
- Minematsu, T., S. Mori, Y. Eizuru, Y. Minamishima, Isolation and analysis of an aciclovir-resistant murine cytomegalovirus mutant 49, 25
- Miniero, R., see Andreone, P. 49, 75
- Mohamed, S.A., A.W. Heath, R. Jennings, A comparison of oral and parenteral routes for therapeutic vaccination with HSV-2 ISCOMs in mice; cytokine profiles, antibody responses and protection 49, 83
- Mori, S., see Minematsu, T. 49, 25
- Mori, S., see Takahashi, K. 49, 15
- Naesens, L., see Neyts, J. 49, 115
- Nakagomi, O., see Takahashi, K. 49, 15

- Neyts, J., E.D. Clercq, The anti-herpesvirus activity of (1'S,2'R)-9-[[1',2'-bis(hydroxymethyl)cycloprop-1'-yl]methyl]guanine is markedly potentiated by the immunosuppressive agent mycophenolate mofetil **49**, 121
- Neyts, J., L. Naesens, C. Ying, L. De Bolle, E. De Clercq, Anti-herpesvirus activity of (1'S,2'R)-9-[[1',2'-bis(hydroxymethyl)-cycloprop-1'-yl]methyl]guanine (A-5021) in vitro and in vivo **49**, 115
- Ohashi, K., see Takahashi, K. **49**, 15
- Okutani, K., see Takahashi, K. **49**, 15
- Prevost, M.-C., see Buonaguro, L. **49**, 35
- Pyke, S.M., see Semple, S.J. **49**, 169
- Reefschläger, J., see Weber, O. **49**, 179
- Reynolds, G.D., see Semple, S.J. **49**, 169
- Ruebsamen-Waigmann, H., see Weber, O. **49**, 179
- Sato, N., see Takahashi, K. **49**, 15
- Scholz, M., H.W. Doerr, J. Cinatl, Inhibition of cytomegalovirus immediate early gene expression: a therapeutic option? **49**, 129
- Semple, S.J., S.M. Pyke, G.D. Reynolds, R.L.P. Flower, In vitro antiviral activity of the anthraquinone chrysophanic acid against poliovirus **49**, 169
- Sharmeen, L., T. McQuade, A. Heldsinger, R. Gogliotti, J. Domagala, S. Gracheck, Inhibition of the early phase of HIV replication by an isothiazolone, PD 161374 **49**, 101
- Shigeta, S., see Takahashi, K. **49**, 15
- Singh, I.P., D.H. Copenhaver, A.K. Chopra, S. Baron, Innate gastrointestinal immunity: characterization of broadly active viral inhibitors **49**, 157
- Stelzner, A., see Henke, A. **49**, 49
- Takahashi, K., M. Matsuda, K. Ohashi, K. Taniguchi, O. Nakagomi, Y. Abe, S. Mori, N. Sato, K. Okutani, S. Shigeta, Analysis of anti-rotavirus activity of extract from *Stevia rebaudiana* **49**, 15
- Taniguchi, K., see Takahashi, K. **49**, 15
- Thust, R., see Wutzler, P. **49**, 55
- Tornesello, M.L., see Buonaguro, L. **49**, 35
- Trappe, J., see Weber, O. **49**, 179
- Turner, R.B., The treatment of rhinovirus infections: progress and potential **49**, 1
- Wagner, R., see Buonaguro, L. **49**, 35
- Weber, O., W. Bender, P. Eckenberg, S. Goldmann, M. Haerter, S. Hallenberger, K. Henninger, J. Reefschläger, J. Trappe, A. Witt-Laido, H. Ruebsamen-Waigmann, Inhibition of murine cytomegalovirus and human cytomegalovirus by a novel non-nucleosidic compound in vivo **49**, 179
- Witt-Laido, A., see Weber, O. **49**, 179
- Wolf, H., see Buonaguro, L. **49**, 35
- Wutzler, P., R. Thust, Genetic risks of antiviral nucleoside analogues – a survey **49**, 55
- Ying, C., see Neyts, J. **49**, 115
- Zambon, M., F. G. Hayden, Position statement: global neuraminidase inhibitor susceptibility network **49**, 147
- Zell, R., see Henke, A. **49**, 49